ACT Genomics Raises $12.5 Million for Genomic Oncology Testing

Taiwan's ACT Genomics, which provides genomic profiles for personalized cancer care, completed a $12.5 million Series B funding. ACT provides genomic profiling assays and next-gen sequencing for use by doctors and pharmas. The company offers targeted therapy treatment options, predictors of immune-checkpoint inhibitor response, and ctDNA-based assays to monitor tumor burden and resistance markers. The round was led by Hotung Group of Taiwan and CDIB Capital Management, the overseas investment arm of China Development Financial. More details.... Share this with colleagues: // //